JPWO2020021341A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020021341A5 JPWO2020021341A5 JP2021504441A JP2021504441A JPWO2020021341A5 JP WO2020021341 A5 JPWO2020021341 A5 JP WO2020021341A5 JP 2021504441 A JP2021504441 A JP 2021504441A JP 2021504441 A JP2021504441 A JP 2021504441A JP WO2020021341 A5 JPWO2020021341 A5 JP WO2020021341A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- dose
- diuretic
- thiazide
- telmisartan
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 35
- RMMXLENWKUUMAY-UHFFFAOYSA-N telmisartan Chemical compound CCCC1=NC2=C(C)C=C(C=3N(C4=CC=CC=C4N=3)C)C=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O RMMXLENWKUUMAY-UHFFFAOYSA-N 0.000 claims 26
- 229940127291 Calcium channel antagonist Drugs 0.000 claims 14
- 239000000480 calcium channel blocker Substances 0.000 claims 14
- 239000005537 C09CA07 - Telmisartan Substances 0.000 claims 13
- 229960005187 telmisartan Drugs 0.000 claims 13
- 239000005458 thiazide-like diuretic Substances 0.000 claims 13
- 206010020772 Hypertension Diseases 0.000 claims 12
- ZPBWCRDSRKPIDG-UHFFFAOYSA-N amlodipine benzenesulfonate Chemical compound OS(=O)(=O)C1=CC=CC=C1.CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl ZPBWCRDSRKPIDG-UHFFFAOYSA-N 0.000 claims 12
- 229960004569 indapamide Drugs 0.000 claims 12
- NDDAHWYSQHTHNT-UHFFFAOYSA-N indapamide Chemical compound CC1CC2=CC=CC=C2N1NC(=O)C1=CC=C(Cl)C(S(N)(=O)=O)=C1 NDDAHWYSQHTHNT-UHFFFAOYSA-N 0.000 claims 12
- 229960004005 amlodipine besylate Drugs 0.000 claims 10
- 238000011287 therapeutic dose Methods 0.000 claims 10
- 102000008873 Angiotensin II receptor Human genes 0.000 claims 9
- 108050000824 Angiotensin II receptor Proteins 0.000 claims 9
- 239000003087 receptor blocking agent Substances 0.000 claims 9
- 239000002934 diuretic Substances 0.000 claims 5
- 230000001882 diuretic effect Effects 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- 239000013543 active substance Substances 0.000 claims 4
- -1 mefluside Chemical compound 0.000 claims 4
- OLNTVTPDXPETLC-XPWALMASSA-N ezetimibe Chemical compound N1([C@@H]([C@H](C1=O)CC[C@H](O)C=1C=CC(F)=CC=1)C=1C=CC(O)=CC=1)C1=CC=C(F)C=C1 OLNTVTPDXPETLC-XPWALMASSA-N 0.000 claims 3
- 229960000815 ezetimibe Drugs 0.000 claims 3
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 claims 3
- 229960000672 rosuvastatin Drugs 0.000 claims 3
- HMJIYCCIJYRONP-UHFFFAOYSA-N (+-)-Isradipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)C1C1=CC=CC2=NON=C12 HMJIYCCIJYRONP-UHFFFAOYSA-N 0.000 claims 2
- PVHUJELLJLJGLN-INIZCTEOSA-N (S)-nitrendipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC([N+]([O-])=O)=C1 PVHUJELLJLJGLN-INIZCTEOSA-N 0.000 claims 2
- YNGDWRXWKFWCJY-UHFFFAOYSA-N 1,4-Dihydropyridine Chemical compound C1C=CNC=C1 YNGDWRXWKFWCJY-UHFFFAOYSA-N 0.000 claims 2
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 claims 2
- ZBIAKUMOEKILTF-UHFFFAOYSA-N 2-[4-[4,4-bis(4-fluorophenyl)butyl]-1-piperazinyl]-N-(2,6-dimethylphenyl)acetamide Chemical compound CC1=CC=CC(C)=C1NC(=O)CN1CCN(CCCC(C=2C=CC(F)=CC=2)C=2C=CC(F)=CC=2)CC1 ZBIAKUMOEKILTF-UHFFFAOYSA-N 0.000 claims 2
- JIVPVXMEBJLZRO-CQSZACIVSA-N 2-chloro-5-[(1r)-1-hydroxy-3-oxo-2h-isoindol-1-yl]benzenesulfonamide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC([C@@]2(O)C3=CC=CC=C3C(=O)N2)=C1 JIVPVXMEBJLZRO-CQSZACIVSA-N 0.000 claims 2
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 claims 2
- LBXHRAWDUMTPSE-AOOOYVTPSA-N 4-chloro-N-[(2S,6R)-2,6-dimethyl-1-piperidinyl]-3-sulfamoylbenzamide Chemical compound C[C@H]1CCC[C@@H](C)N1NC(=O)C1=CC=C(Cl)C(S(N)(=O)=O)=C1 LBXHRAWDUMTPSE-AOOOYVTPSA-N 0.000 claims 2
- RZTAMFZIAATZDJ-HNNXBMFYSA-N 5-o-ethyl 3-o-methyl (4s)-4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC(Cl)=C1Cl RZTAMFZIAATZDJ-HNNXBMFYSA-N 0.000 claims 2
- KJEBULYHNRNJTE-DHZHZOJOSA-N Cinalong Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC\C=C\C=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 KJEBULYHNRNJTE-DHZHZOJOSA-N 0.000 claims 2
- NENBAISIHCWPKP-UHFFFAOYSA-N Clofenamide Chemical compound NS(=O)(=O)C1=CC=C(Cl)C(S(N)(=O)=O)=C1 NENBAISIHCWPKP-UHFFFAOYSA-N 0.000 claims 2
- VPMWFZKOWULPGT-UHFFFAOYSA-N Clorexolone Chemical compound C1C=2C=C(Cl)C(S(=O)(=O)N)=CC=2C(=O)N1C1CCCCC1 VPMWFZKOWULPGT-UHFFFAOYSA-N 0.000 claims 2
- 208000032928 Dyslipidaemia Diseases 0.000 claims 2
- XQLWNAFCTODIRK-UHFFFAOYSA-N Gallopamil Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC(OC)=C(OC)C(OC)=C1 XQLWNAFCTODIRK-UHFFFAOYSA-N 0.000 claims 2
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 2
- FNQQBFNIYODEMB-UHFFFAOYSA-N Meticrane Chemical compound C1CCS(=O)(=O)C2=C1C=C(C)C(S(N)(=O)=O)=C2 FNQQBFNIYODEMB-UHFFFAOYSA-N 0.000 claims 2
- HBNPJJILLOYFJU-VMPREFPWSA-N Mibefradil Chemical compound C1CC2=CC(F)=CC=C2[C@H](C(C)C)[C@@]1(OC(=O)COC)CCN(C)CCCC1=NC2=CC=CC=C2N1 HBNPJJILLOYFJU-VMPREFPWSA-N 0.000 claims 2
- FAIIFDPAEUKBEP-UHFFFAOYSA-N Nilvadipine Chemical compound COC(=O)C1=C(C#N)NC(C)=C(C(=O)OC(C)C)C1C1=CC=CC([N+]([O-])=O)=C1 FAIIFDPAEUKBEP-UHFFFAOYSA-N 0.000 claims 2
- 229960000528 amlodipine Drugs 0.000 claims 2
- 229960002992 barnidipine Drugs 0.000 claims 2
- VXMOONUMYLCFJD-DHLKQENFSA-N barnidipine Chemical compound C1([C@@H]2C(=C(C)NC(C)=C2C(=O)OC)C(=O)O[C@@H]2CN(CC=3C=CC=CC=3)CC2)=CC=CC([N+]([O-])=O)=C1 VXMOONUMYLCFJD-DHLKQENFSA-N 0.000 claims 2
- UIEATEWHFDRYRU-UHFFFAOYSA-N bepridil Chemical compound C1CCCN1C(COCC(C)C)CN(C=1C=CC=CC=1)CC1=CC=CC=C1 UIEATEWHFDRYRU-UHFFFAOYSA-N 0.000 claims 2
- 229960003665 bepridil Drugs 0.000 claims 2
- 229960001523 chlortalidone Drugs 0.000 claims 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 2
- 229960003020 cilnidipine Drugs 0.000 claims 2
- 229960003597 clevidipine Drugs 0.000 claims 2
- KPBZROQVTHLCDU-GOSISDBHSA-N clevidipine Chemical compound CCCC(=O)OCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@H]1C1=CC=CC(Cl)=C1Cl KPBZROQVTHLCDU-GOSISDBHSA-N 0.000 claims 2
- 229960002883 clofenamide Drugs 0.000 claims 2
- 229960004070 clopamide Drugs 0.000 claims 2
- 229960005315 clorexolone Drugs 0.000 claims 2
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 claims 2
- 229960004166 diltiazem Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229960003580 felodipine Drugs 0.000 claims 2
- 229960002637 fenquizone Drugs 0.000 claims 2
- DBDTUXMDTSTPQZ-UHFFFAOYSA-N fenquizone Chemical compound N1C=2C=C(Cl)C(S(=O)(=O)N)=CC=2C(=O)NC1C1=CC=CC=C1 DBDTUXMDTSTPQZ-UHFFFAOYSA-N 0.000 claims 2
- 229960000457 gallopamil Drugs 0.000 claims 2
- 229960004427 isradipine Drugs 0.000 claims 2
- 229960004294 lercanidipine Drugs 0.000 claims 2
- ZDXUKAKRHYTAKV-UHFFFAOYSA-N lercanidipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)(C)CN(C)CCC(C=2C=CC=CC=2)C=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZDXUKAKRHYTAKV-UHFFFAOYSA-N 0.000 claims 2
- 229960001941 lidoflazine Drugs 0.000 claims 2
- 229960003963 manidipine Drugs 0.000 claims 2
- ANEBWFXPVPTEET-UHFFFAOYSA-N manidipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN2CCN(CC2)C(C=2C=CC=CC=2)C=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ANEBWFXPVPTEET-UHFFFAOYSA-N 0.000 claims 2
- VKQFCGNPDRICFG-UHFFFAOYSA-N methyl 2-methylpropyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCC(C)C)C1C1=CC=CC=C1[N+]([O-])=O VKQFCGNPDRICFG-UHFFFAOYSA-N 0.000 claims 2
- 229960003738 meticrane Drugs 0.000 claims 2
- 229960002817 metolazone Drugs 0.000 claims 2
- AQCHWTWZEMGIFD-UHFFFAOYSA-N metolazone Chemical compound CC1NC2=CC(Cl)=C(S(N)(=O)=O)C=C2C(=O)N1C1=CC=CC=C1C AQCHWTWZEMGIFD-UHFFFAOYSA-N 0.000 claims 2
- 229960004438 mibefradil Drugs 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 229960001597 nifedipine Drugs 0.000 claims 2
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 claims 2
- 229960005366 nilvadipine Drugs 0.000 claims 2
- 229960000715 nimodipine Drugs 0.000 claims 2
- 229960000227 nisoldipine Drugs 0.000 claims 2
- 229960005425 nitrendipine Drugs 0.000 claims 2
- 229960001722 verapamil Drugs 0.000 claims 2
- 229960000537 xipamide Drugs 0.000 claims 2
- MTZBBNMLMNBNJL-UHFFFAOYSA-N xipamide Chemical compound CC1=CC=CC(C)=C1NC(=O)C1=CC(S(N)(=O)=O)=C(Cl)C=C1O MTZBBNMLMNBNJL-UHFFFAOYSA-N 0.000 claims 2
- 239000005485 Azilsartan Substances 0.000 claims 1
- 239000002083 C09CA01 - Losartan Substances 0.000 claims 1
- 239000002080 C09CA02 - Eprosartan Substances 0.000 claims 1
- 239000004072 C09CA03 - Valsartan Substances 0.000 claims 1
- 239000002947 C09CA04 - Irbesartan Substances 0.000 claims 1
- 239000002053 C09CA06 - Candesartan Substances 0.000 claims 1
- 239000005480 Olmesartan Substances 0.000 claims 1
- KGSXMPPBFPAXLY-UHFFFAOYSA-N azilsartan Chemical compound CCOC1=NC2=CC=CC(C(O)=O)=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C1=NOC(=O)N1 KGSXMPPBFPAXLY-UHFFFAOYSA-N 0.000 claims 1
- 229960002731 azilsartan Drugs 0.000 claims 1
- 229960000932 candesartan Drugs 0.000 claims 1
- SGZAIDDFHDDFJU-UHFFFAOYSA-N candesartan Chemical compound CCOC1=NC2=CC=CC(C(O)=O)=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SGZAIDDFHDDFJU-UHFFFAOYSA-N 0.000 claims 1
- 235000012000 cholesterol Nutrition 0.000 claims 1
- 229960004563 eprosartan Drugs 0.000 claims 1
- OROAFUQRIXKEMV-LDADJPATSA-N eprosartan Chemical compound C=1C=C(C(O)=O)C=CC=1CN1C(CCCC)=NC=C1\C=C(C(O)=O)/CC1=CC=CS1 OROAFUQRIXKEMV-LDADJPATSA-N 0.000 claims 1
- 229960002198 irbesartan Drugs 0.000 claims 1
- YCPOHTHPUREGFM-UHFFFAOYSA-N irbesartan Chemical group O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 claims 1
- 229960004773 losartan Drugs 0.000 claims 1
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 claims 1
- VTRAEEWXHOVJFV-UHFFFAOYSA-N olmesartan Chemical compound CCCC1=NC(C(C)(C)O)=C(C(O)=O)N1CC1=CC=C(C=2C(=CC=CC=2)C=2NN=NN=2)C=C1 VTRAEEWXHOVJFV-UHFFFAOYSA-N 0.000 claims 1
- 229960005117 olmesartan Drugs 0.000 claims 1
- 229960004699 valsartan Drugs 0.000 claims 1
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024062293A JP2024099574A (ja) | 2018-07-26 | 2024-04-08 | 高血圧症の処置のための組成物 |
| JP2025175743A JP2026031933A (ja) | 2018-07-26 | 2025-10-17 | 高血圧症の処置のための組成物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862703802P | 2018-07-26 | 2018-07-26 | |
| US62/703,802 | 2018-07-26 | ||
| PCT/IB2019/000923 WO2020021341A1 (en) | 2018-07-26 | 2019-07-26 | Compositions for the treatment of hypertension |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024062293A Division JP2024099574A (ja) | 2018-07-26 | 2024-04-08 | 高血圧症の処置のための組成物 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022511588A JP2022511588A (ja) | 2022-02-01 |
| JPWO2020021341A5 true JPWO2020021341A5 (https=) | 2022-08-02 |
| JP2022511588A5 JP2022511588A5 (https=) | 2022-08-02 |
| JP7474738B2 JP7474738B2 (ja) | 2024-04-25 |
Family
ID=69179579
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021504441A Active JP7474738B2 (ja) | 2018-07-26 | 2019-07-26 | 高血圧症の処置のための組成物 |
| JP2024062293A Pending JP2024099574A (ja) | 2018-07-26 | 2024-04-08 | 高血圧症の処置のための組成物 |
| JP2025175743A Pending JP2026031933A (ja) | 2018-07-26 | 2025-10-17 | 高血圧症の処置のための組成物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024062293A Pending JP2024099574A (ja) | 2018-07-26 | 2024-04-08 | 高血圧症の処置のための組成物 |
| JP2025175743A Pending JP2026031933A (ja) | 2018-07-26 | 2025-10-17 | 高血圧症の処置のための組成物 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20200030296A1 (https=) |
| EP (1) | EP3826633A4 (https=) |
| JP (3) | JP7474738B2 (https=) |
| KR (1) | KR20210038931A (https=) |
| CN (1) | CN112770746A (https=) |
| AU (2) | AU2019309329B2 (https=) |
| BR (1) | BR112021001374A2 (https=) |
| CA (1) | CA3107616A1 (https=) |
| MX (2) | MX2021001043A (https=) |
| WO (1) | WO2020021341A1 (https=) |
| ZA (1) | ZA202006591B (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20240096848A (ko) | 2017-01-25 | 2024-06-26 | 더 조지 인스티튜트 포 글로벌 헬스 | 고혈압의 치료를 위한 조성물 |
| US12521380B2 (en) * | 2017-01-25 | 2026-01-13 | The George Institute for Global Health | Compositions for the treatment of hypertension |
| WO2025226012A1 (ko) * | 2024-04-23 | 2025-10-30 | 신풍제약주식회사 | 칸데사르탄, 암로디핀 및 인다파미드를 포함하는 고혈압 예방 또는 치료용 약제학적 복합제제 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GT199800126A (es) * | 1997-08-29 | 2000-01-29 | Terapia de combinacion. | |
| GB2361185A (en) * | 2000-04-10 | 2001-10-17 | Nicholas J Wald | Pharmaceutical formulation for the prevention of cardiovascular disease |
| EG24716A (en) | 2002-05-17 | 2010-06-07 | Novartis Ag | Combination of organic compounds |
| US20040198789A1 (en) * | 2003-02-28 | 2004-10-07 | Recordati Ireland Limited | Lercanidipine/ARB/diuretic therapeutic combinations |
| KR100582347B1 (ko) * | 2004-12-30 | 2006-05-22 | 한미약품 주식회사 | 3-하이드록시-3-메틸글루타릴 조효소 ａ 환원효소 억제제및 고혈압 치료제의 복합제제 및 그의 제조방법 |
| US20070293552A1 (en) * | 2006-06-15 | 2007-12-20 | Gorczynski Richard J | Antihypertensive therapy method |
| EP2545920A1 (en) * | 2007-08-22 | 2013-01-16 | Abbott GmbH & Co. KG | Therapy for complications of diabetes |
| KR20090057538A (ko) * | 2007-12-03 | 2009-06-08 | 박사룡 | 안지오텐신 투 안타고니스트, 칼슘 안타고니스트 및이뇨제를 함유하는 고혈압 치료제 조성물 |
| DE102008059206A1 (de) * | 2008-11-27 | 2010-06-10 | Bayer Schering Pharma Aktiengesellschaft | Pharmazeutische Darreichungsform enthaltend Nifedipin oder Nisoldipin und einen Angiotensin-II Antagonisten und/oder ein Diuretikum |
| CN101618215A (zh) * | 2009-08-16 | 2010-01-06 | 王丽燕 | 含钙拮抗剂、aⅱ受体拮抗剂和他汀类药的药物组合物 |
| EP2575808A1 (en) * | 2010-05-28 | 2013-04-10 | Mahmut Bilgic | Combination of antihypertensive agents |
| CZ2015687A3 (cs) * | 2015-10-02 | 2017-04-12 | Zentiva, K.S. | Farmaceutická kompozice obsahující kombinaci kandesartanu, amlodipinu a hydrochlorthiazidu |
| US10369156B2 (en) * | 2016-11-15 | 2019-08-06 | The George Institute for Global Health | Compositions for the treatment of hypertension |
-
2019
- 2019-07-26 MX MX2021001043A patent/MX2021001043A/es unknown
- 2019-07-26 WO PCT/IB2019/000923 patent/WO2020021341A1/en not_active Ceased
- 2019-07-26 KR KR1020217005757A patent/KR20210038931A/ko not_active Ceased
- 2019-07-26 EP EP19841262.9A patent/EP3826633A4/en active Pending
- 2019-07-26 CN CN201980063218.2A patent/CN112770746A/zh active Pending
- 2019-07-26 AU AU2019309329A patent/AU2019309329B2/en active Active
- 2019-07-26 BR BR112021001374A patent/BR112021001374A2/pt active IP Right Grant
- 2019-07-26 CA CA3107616A patent/CA3107616A1/en active Pending
- 2019-07-26 JP JP2021504441A patent/JP7474738B2/ja active Active
- 2019-07-26 US US16/523,230 patent/US20200030296A1/en not_active Abandoned
-
2020
- 2020-10-22 ZA ZA2020/06591A patent/ZA202006591B/en unknown
-
2021
- 2021-01-26 MX MX2025000236A patent/MX2025000236A/es unknown
-
2022
- 2022-12-16 US US18/067,335 patent/US20230125076A1/en not_active Abandoned
-
2024
- 2024-04-08 JP JP2024062293A patent/JP2024099574A/ja active Pending
-
2025
- 2025-03-13 AU AU2025201831A patent/AU2025201831A1/en active Pending
- 2025-10-17 JP JP2025175743A patent/JP2026031933A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2019126749A (ru) | Композиции для лечения гипертензии | |
| CA2613417A1 (en) | Pharmaceutical preparation containing an angiotensin ii receptor antagonist and a calcium channel blocker | |
| JP2020506180A5 (https=) | ||
| RU2004137105A (ru) | Комбинация органических соединений | |
| JP2022511588A5 (https=) | ||
| RU2014111474A (ru) | Способы лечения сердечно-сосудистых нарушений | |
| NZ596395A (en) | Stable solid benzimidazole derivative preparation having optimized dissolution property | |
| HRP20120667T2 (hr) | Derivat benzimidazola i njegova uporaba kao antagonista aii receptora | |
| JP2010529205A5 (https=) | ||
| AR039329A1 (es) | Derivados de triazol, antagonistas de receptor de taquicinina | |
| RU2001102585A (ru) | Гипотензивная комбинация валсартана и блокатора кальциевых каналов | |
| EP1870098A2 (en) | Combined use of valsartan and calcium channel blockers for therapeutic purposes | |
| JP2005523254A5 (https=) | ||
| PE20142101A1 (es) | Composiciones farmaceuticas de aliskiren | |
| JPWO2020021341A5 (https=) | ||
| JP2007507519A5 (https=) | ||
| NO20060195L (no) | Kinolylamidderivater som CCR-5-antagonister | |
| JP2019536816A5 (https=) | ||
| PE20110844A1 (es) | Composicion farmaceutica solida | |
| ES2637024T3 (es) | Composición farmacéutica para el tratamiento de enfermedades inflamatorias mediadas por MCP-1 | |
| ECSP044973A (es) | Nuevas formas polimorficas cristalinas de clorhidrato de lercanidipina y proceso para su preparacion | |
| RU2021103512A (ru) | Композиции для лечения гипертензии | |
| CZ2015687A3 (cs) | Farmaceutická kompozice obsahující kombinaci kandesartanu, amlodipinu a hydrochlorthiazidu | |
| WO2007039462A3 (en) | Indane derivatives as mch receptor antagonists | |
| JP2018111736A (ja) | 高血圧症の予防又は治療のための併用医薬 |